Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer
Phase 3
Completed
- Conditions
- Gynaecologic or Digestive Pelvic Cancer
- Interventions
- Drug: Isolated pelvis perfusionRadiation: radiotherapyProcedure: Surgery
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 101
- Registration Number
- NCT00949039
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Phase 2
Completed
- Conditions
- Metastatic, Cerebral Primitive Neuroectodermal Tumors
- Interventions
- Drug: Chemotherapy (carboplatin, etoposide, thiotepa)
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 68
- Registration Number
- NCT00936156
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 100
- Registration Number
- NCT00935675
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
Phase 2
Completed
- Conditions
- Solid TumorsBrain TumorsNeuroblastoma
- Interventions
- Drug: Temozolomide/Hycamtin (Topotecan)
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 129
- Registration Number
- NCT00918320
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy
Phase 1
- Conditions
- Cervical CancerPrecancerous Condition
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 24
- Registration Number
- NCT00811408
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
Phase 1
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2010-10-07
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 58
- Registration Number
- NCT00811759
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 150
- Registration Number
- NCT00552149
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
Phase 2
Completed
- Conditions
- Colorectal CancerMetastatic Cancer
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 45
- Registration Number
- NCT00544349
- Locations
- 🇫🇷
Centre Eugene Marquis, Rennes, France
🇫🇷Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇫🇷Centre Regional Francois Baclesse, Caen, France
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
Phase 3
- Conditions
- Thyroid Cancer
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2007-02-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 950
- Registration Number
- NCT00435851
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Image Guided Radiation Therapy For Prostate Cancer
Phase 3
Completed
- Conditions
- Prostate Cancer
- Interventions
- Procedure: Control position by 3DOBI before the fractionProcedure: Standard imaging
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 470
- Registration Number
- NCT00433706
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
© Copyright 2025. All Rights Reserved by MedPath